Mobile

A Randomized, Double-Blind, Placebo-controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-000512-17

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine the treatment effect of AMG 162 compared with placebo on lumbar spine bone mineral density (BMD) in men with nonmetastatic prostate cancer undergoing ADT.

Critère d'inclusion

  • Bone loss in patients undergoing androgen-deprivation therapy (ADT) for non-metastatic prostate cancer

Liens